3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Anemia, Refractory, with Excess of Blasts
2
Lymphoma, Mantle-Cell
1
Hemoglobinuria, Paroxysmal
1
Glioblastoma
1
Anemia, Aplastic
1
Interventions
Temozolomide
115
Bevacizumab
72
Radiotherapy
52
Radiation
23
Erlotinib Hydrochloride
13
Lomustine
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
11
Vorinostat
10
Nivolumab
10
Surgical Procedures, Operative
9
Irinotecan
9
Sorafenib
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
7
Immunoglobulin G
7
Everolimus
7
Drug Therapy
7
Disulfides
7
Radiosurgery
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Carmustine
6
antineoplaston AS 2-1
5
antineoplaston A10
5
Sirolimus
5
Cilengitide
5
veliparib
4
veledimex
4
temsirolimus
4
selinexor
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Glioblastoma
×
Basiliximab
×
Clear all
NCT02366728
2023-06-08
ELEVATE
Duke University
Phase 2
Completed
64 enrolled
17 charts